Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Synthesis, Conformational Analysis and Antiviral and Antitumoral Activity of New 1,2‐Disubstituted Carbocyclic Nucleosides. — Lourdes Santana (2003) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Synthesis, Conformational Analysis and Antiviral and Antitumoral Activity of New 1,2‐Disubstituted Carbocyclic Nucleosides.
Shared by
De Clercq Erik
KU Leuven
Synthesis, Conformational Analysis and Antiviral and Antitumoral Activity of New 1,2‐Disubstituted Carbocyclic Nucleosides.
Article
2003
en
Authors
+2 more
LS
Lourdes Santana
MT
Marta Teijeira
EU
Eugenio Uriarte
Abstract
1 min read
Abstract For Abstract see ChemInform Abstract in Full Text.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2002
Synthesis, conformational analysis and antiviral and antitumoral activity of new 1,2-disubstituted carbocyclic nucleosides
Lourdes Santana
,
Marta Teijeira
,
Eugenio Uriarte
,
Jan Balzarini
,
De Clercq Erik
Article
2000
ChemInform Abstract: Design, Synthesis, Conformational Analysis and Biological Activities of Purine‐Based 1,2‐Disubstituted Carbocyclic Nucleosides.
Carmen Terán
,
Lourdes Santana
,
Marta Teijeira
,
Uriarte Eugenio Uriarte Eugenio
,
De Clercq Erik
Article
2004
Purine Derivatives of 1,2‐Disubstituted Cyclohexane Analogues of Nucleosides.
Carmen Terán
,
Lourdes Santana
,
Eugenio Uriarte
,
Dolores Viña
,
De Clercq Erik
Article
2004
Carbocyclic Analogues of Nucleosides from bis‐(Hydroxymethyl)cyclopentane: Synthesis, Antiviral and Cytostatic Activities of Adenosine, Inosine and Uridine Analogues.
José Manuel Blanco
,
Olga Caamaño
,
Franco Fernández
,
José E. Rodríguez‐Borges
,
Jan Balzarini
,
De Clercq Erik
Article
2004
Synthesis and Biological Evaluation of Some Acyclic 4,6‐Disubstituted 1H‐Pyrazolo[3,4‐d]pyrimidine Nucleosides
Omar Moukha‐Chafiq
,
M. L. Taha
,
A. Mouma
,
Hassan B. Lazrek
,
Jean‐Jacques Vasseur
,
De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.